Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 54Genitourinary 29Other hematologic neoplasm 16Plasma cell 5Tumor-Agnostic 4Myeloid 4Dermatologic 4Thoracic 3Other solid neoplasm 2Gynecologic 2Breast 2Sarcoma 1Other neoplasm 1Gastrointestinal 1Classical hematology 1

Conditions

Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 108Carboplatin 96pembrolizumab 63Cisplatin 62Cyclophosphamide 44Bevacizumab 35Taxes 31Gemcitabine 28liposomal doxorubicin 27Topotecan 26fludarabine 24olaparib 22Nivolumab 20Docetaxel 20Radiotherapy 18Brachytherapy 17veliparib 16Magnetic Resonance Spectroscopy 16Doxorubicin 16Biopsy 15Radiation 14niraparib 13aldesleukin 13Specimen Handling 13Platinum 13Oxaliplatin 13Filgrastim 13Albumin-Bound Paclitaxel 12atezolizumab 11Interleukin-2 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Prednisone × Gynecologic × Clear all
NCT06421935 2026-03-24

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

EMD Serono

Phase 1 Active not recruiting
141 enrolled
Gynecologic

Ovarian Neoplasms

NCT04726332 2024-05-14

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Exelixis

Phase 1 Terminated
52 enrolled
BreastGynecologic

Carcinoma, Ovarian Epithelial, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡